Ładuje się......
The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance
HER2 is a well-known oncogenic receptor tyrosine kinase. HER2 gene amplification occurs in about 20% of breast cancer (BC), which leads to overexpression of HER2 protein, known as HER2-positive BC. Inhibitors of HER2 have significantly improved the prognosis of patients with this subset of BC. Since...
Zapisane w:
| Wydane w: | Pharmacol Ther |
|---|---|
| 1. autor: | |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
2020
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7855784/ https://ncbi.nlm.nih.gov/pubmed/32898548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pharmthera.2020.107677 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|